Abortion Pill’s Safety Called into Question in Congressional Actions Based on Misleading Data — The Monitor
False claims about the safety of mifepristone are driving legislative and investigative action in Congress, even as major medical organizations and decades of clinical evidence support the drug’s safety. And competing interpretations of what censorship and free speech mean are impacting how health m
By KFF Health News
· Apr 9, 2026
· via KFF Health News
Image: KFF Health News
Tags
policyformat:headlineheadlineKFF Health News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Policy
All Policy →
PolicyFierceBiotech ↗
China’s biotech rise has been a persistent concern for federal health leaders, Congress, and many biopharma ex…
PolicyFierceBiotech ↗
Asked by Fierce if he'd consider returning to the FDA, Pazdur said he wouldn't serve again under the Trump adm…
PolicyBriefing
Using the Kemp-Kasten amendment, the administration withheld $32.5 million in FY2025 UNFPA support and is expe…